{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:44:30Z","timestamp":1793105070645,"version":"4.5.0"},"reference-count":118,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-010680"],"award-info":[{"award-number":["INV-010680"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-010680"],"award-info":[{"award-number":["INV-010680"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-010680"],"award-info":[{"award-number":["INV-010680"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-010680"],"award-info":[{"award-number":["INV-010680"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-010680"],"award-info":[{"award-number":["INV-010680"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-010680"],"award-info":[{"award-number":["INV-010680"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-010680"],"award-info":[{"award-number":["INV-010680"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-010680"],"award-info":[{"award-number":["INV-010680"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-010680"],"award-info":[{"award-number":["INV-010680"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-010680"],"award-info":[{"award-number":["INV-010680"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["DGE-1762114"],"award-info":[{"award-number":["DGE-1762114"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016820","name":"Vaccine Research Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016820","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>A vaccine that provides robust, durable protection against malaria remains a global health priority. Although a breakthrough in the fight against malaria has recently been achieved by the licensure of two vaccines based on the circumsporozoite protein (CSP), the effectiveness and durability of protection can still be improved. Both vaccines contain a portion of CSP that does not include epitopes targeted by recently identified, potently protective monoclonal antibodies, suggesting that newer immunogens can expand the breadth of immunity and potentially increase protection. Here we explored &gt;100 alternative CSP-based immunogens and evaluated the immunogenicity and protection of a large number of candidates, comparing several to the licensed R21 vaccine. The data highlight several general features that improve the stability and immunogenicity of CSP-based vaccines, such as inclusion of the C-terminal domain and high-density display on protein nanoparticle scaffolds. We also identify antigen design strategies that do not warrant further exploration, such as synthetic repeat regions that include non-native repeat cadences. The benchmark R21 vaccine outperformed our best immunogen for immunogenicity and protection. Overall, our data provide valuable insights on the inclusion of junctional region epitopes that will guide the development of potent and durable vaccines against malaria.<\/jats:p>","DOI":"10.1038\/s41541-025-01140-x","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T06:59:51Z","timestamp":1746428391000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Elicitation of liver-stage immunity by nanoparticle immunogens displaying P. falciparum CSP-derived antigens"],"prefix":"10.1038","volume":"10","author":[{"given":"Mark D.","family":"Langowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph R.","family":"Francica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex L.","family":"Roederer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas K.","family":"Hurlburt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justas V.","family":"Rodarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lais","family":"Da Silva Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara J.","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Bonilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlon","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patience","family":"Kiyuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Ravichandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connor","family":"Weidle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mangala","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary R.","family":"Matyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Pepper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azza H.","family":"Idris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Seder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Pancera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil P.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,5]]},"reference":[{"key":"1140_CR1","unstructured":"WHO. World Malaria Report 2023. https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2023 (2023)."},{"key":"1140_CR2","doi-asserted-by":"publisher","first-page":"eaau1458","DOI":"10.1126\/scitranslmed.aau1458","volume":"11","author":"JG Beeson","year":"2019","unstructured":"Beeson, J. G. et al. Challenges and strategies for developing efficacious and long-lasting malaria vaccines. Sci. Transl. Med. 11, eaau1458 (2019).","journal-title":"Sci. Transl. Med."},{"key":"1140_CR3","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1016\/S1473-3099(15)00239-X","volume":"15","author":"MT White","year":"2015","unstructured":"White, M. T. et al. Immunogenicity of the RTS,S\/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial. Lancet Infect. Dis. 15, 1450\u20131458 (2015).","journal-title":"Lancet Infect. Dis."},{"key":"1140_CR4","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1084\/jem.154.4.1225","volume":"154","author":"N Yoshida","year":"1981","unstructured":"Yoshida, N., Potocnjak, P., Nussenzweig, V. & Nussenzweig, R. S. Biosynthesis of Pb44, the protective antigen of sporozoites of Plasmodium berghei. J. Exp. Med. 154, 1225\u20131236 (1981).","journal-title":"J. Exp. Med."},{"key":"1140_CR5","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0140-6736(23)02511-4","volume":"403","author":"MS Datoo","year":"2024","unstructured":"Datoo, M. S. et al. Safety and efficacy of malaria vaccine candidate R21\/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial. Lancet 403, 533\u2013544 (2024).","journal-title":"Lancet"},{"key":"1140_CR6","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1056\/NEJMoa1102287","volume":"365","author":"The RTS,S Clinical Trials Partnership","year":"2011","unstructured":"The RTS,S Clinical Trials Partnership First results of phase 3 trial of RTS,S\/AS01 malaria vaccine in African children. N. Engl. J. Med. 365, 1863\u20131875 (2011).","journal-title":"N. Engl. J. Med."},{"key":"1140_CR7","unstructured":"WHO. Who Recommends Groundbreaking Malaria Vaccine For Children At Risk. https:\/\/www.who.int\/news\/item\/06-10-2021-who-recommends-groundbreaking-malaria-vaccine-for-children-at-risk (2025)."},{"key":"1140_CR8","unstructured":"WHO. Who Recommends R21\/matrix-m Vaccine For Malaria Prevention In Updated Advice On Immunization. https:\/\/www.who.int\/news\/item\/02-10-2023-who-recommends-r21-matrix-m-vaccine-for-malaria-prevention-in-updated-advice-on-immunization (2025)."},{"key":"1140_CR9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1084\/jem.20040989","volume":"201","author":"A Coppi","year":"2005","unstructured":"Coppi, A., Pinzon-Ortiz, C., Hutter, C. & Sinnis, P. The Plasmodium circumsporozoite protein is proteolytically processed during cell invasion. J. Exp. Med. 201, 27\u201333 (2005).","journal-title":"J. Exp. Med."},{"key":"1140_CR10","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.chom.2007.10.002","volume":"2","author":"A Coppi","year":"2007","unstructured":"Coppi, A. et al. Heparan sulfate proteoglycans provide a signal to Plasmodium sporozoites to stop migrating and productively invade host cells. Cell Host Microbe 2, 316\u2013327 (2007).","journal-title":"Cell Host Microbe"},{"key":"1140_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1001318","volume":"7","author":"IA Cockburn","year":"2011","unstructured":"Cockburn, I. A. et al. Dendritic cells and hepatocytes use distinct pathways to process protective antigen from plasmodium in vivo. PLoS Pathog. 7, e1001318 (2011).","journal-title":"PLoS Pathog."},{"key":"1140_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/srep01990","volume":"3","author":"NM Bowman","year":"2013","unstructured":"Bowman, N. M. et al. Comparative population structure of Plasmodium falciparum circumsporozoite protein NANP repeat lengths in Lilongwe, Malawi. Sci. Rep. 3, 1990 (2013).","journal-title":"Sci. Rep."},{"key":"1140_CR13","doi-asserted-by":"publisher","first-page":"7817","DOI":"10.1073\/pnas.1205737109","volume":"109","author":"MB Doud","year":"2012","unstructured":"Doud, M. B. et al. Unexpected fold in the circumsporozoite protein target of malaria vaccines. Proc. Natl Acad. Sci. USA. 109, 7817\u20137822 (2012).","journal-title":"Proc. Natl Acad. Sci. USA."},{"key":"1140_CR14","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/nm.4512","volume":"24","author":"NK Kisalu","year":"2018","unstructured":"Kisalu, N. K. et al. A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. Nat. Med. 24, 408\u2013416 (2018).","journal-title":"Nat. Med."},{"key":"1140_CR15","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nm.4513","volume":"24","author":"J Tan","year":"2018","unstructured":"Tan, J. et al. A public antibody lineage that potently inhibits malaria infection through dual binding to the circumsporozoite protein. Nat. Med. 24, 401\u2013407 (2018).","journal-title":"Nat. Med."},{"key":"1140_CR16","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.immuni.2020.08.014","volume":"53","author":"LT Wang","year":"2020","unstructured":"Wang, L. T. et al. A potent anti-malarial human monoclonal antibody targets circumsporozoite protein minor repeats and neutralizes sporozoites in the liver. Immunity 53, 733\u2013744.e8 (2020).","journal-title":"Immunity"},{"key":"1140_CR17","doi-asserted-by":"publisher","first-page":"e1010042","DOI":"10.1371\/journal.ppat.1010042","volume":"17","author":"Y Flores-Garcia","year":"2021","unstructured":"Flores-Garcia, Y. et al. The P. falciparum CSP repeat region contains three distinct epitopes required for protection by antibodies in vivo. PLoS Pathog. 17, e1010042 (2021).","journal-title":"PLoS Pathog."},{"key":"1140_CR18","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1056\/NEJMoa2206966","volume":"387","author":"K Kayentao","year":"2022","unstructured":"Kayentao, K. et al. Safety and efficacy of a monoclonal antibody against malaria in Mali. N. Engl. J. Med. 387, 1833\u20131842 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1140_CR19","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1056\/NEJMoa2312775","volume":"390","author":"Kassoum Kayentao","year":"2024","unstructured":"Kayentao, K. assoum et al. Subcutaneous administration of a monoclonal antibody to prevent malaria. N. Engl. J. Med. 390, 1549\u20131559 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1140_CR20","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1016\/S0140-6736(21)00943-0","volume":"397","author":"MS Datoo","year":"2021","unstructured":"Datoo, M. S. et al. Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial. Lancet 397, 1809\u20131818 (2021).","journal-title":"Lancet"},{"key":"1140_CR21","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1084\/jem.20151960","volume":"213","author":"R Rappuoli","year":"2016","unstructured":"Rappuoli, R., Bottomley, M. J., D\u2019Oro, U., Finco, O. & De Gregorio, E. Reverse vaccinology 2.0: human immunology instructs vaccine antigen design. J. Exp. Med. 213, 469\u2013481 (2016).","journal-title":"J. Exp. Med."},{"key":"1140_CR22","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2209604","volume":"388","author":"Alberto Papi","year":"2023","unstructured":"Papi, A. lberto et al. Respiratory syncytial virus prefusion F protein vaccine in older adults. N. Engl. J. Med. 388, 595\u2013608 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1140_CR23","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1056\/NEJMoa2213836","volume":"388","author":"E Walsh Edward","year":"2023","unstructured":"Walsh Edward, E. et al. Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults. N. Engl. J. Med. 388, 1465\u20131477 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1140_CR24","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"P Polack Fernando","year":"2020","unstructured":"Polack Fernando, P. et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1140_CR25","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"R Baden Lindsey","year":"2021","unstructured":"Baden Lindsey, R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1140_CR26","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","volume":"384","author":"J Sadoff","year":"2021","unstructured":"Sadoff, J. et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against covid-19. N. Engl. J. Med. 384, 2187\u20132201 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1140_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-34171-7","volume":"8","author":"RN Kirchdoerfer","year":"2018","unstructured":"Kirchdoerfer, R. N. et al. Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis. Sci. Rep. 8, 15701 (2018).","journal-title":"Sci. Rep."},{"key":"1140_CR28","doi-asserted-by":"publisher","first-page":"E7348","DOI":"10.1073\/pnas.1707304114","volume":"114","author":"J Pallesen","year":"2017","unstructured":"Pallesen, J. et al. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc. Natl Acad. Sci. Usa. 114, E7348\u2013E7357 (2017).","journal-title":"Proc. Natl Acad. Sci. Usa."},{"key":"1140_CR29","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1126\/science.1243283","volume":"342","author":"JS McLellan","year":"2013","unstructured":"McLellan, J. S. et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342, 592\u2013598 (2013).","journal-title":"Science"},{"key":"1140_CR30","doi-asserted-by":"publisher","first-page":"E10438","DOI":"10.1073\/pnas.1715812114","volume":"114","author":"D Oyen","year":"2017","unstructured":"Oyen, D. et al. Structural basis for antibody recognition of the NANP repeats in plasmodium falciparum circumsporozoite protein. Proc. Natl Acad. Sci. Usa. 114, E10438\u2013E10445 (2017).","journal-title":"Proc. Natl Acad. Sci. Usa."},{"key":"1140_CR31","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/j.immuni.2017.11.007","volume":"47","author":"G Triller","year":"2017","unstructured":"Triller, G. et al. Natural parasite exposure induces protective human anti-malarial antibodies. Immunity 47, 1197\u20131209.e10 (2017).","journal-title":"Immunity"},{"key":"1140_CR32","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1126\/science.aar5304","volume":"360","author":"K Imkeller","year":"2018","unstructured":"Imkeller, K. et al. Antihomotypic affinity maturation improves human B cell responses against a repetitive epitope. Science 360, 1358\u20131362 (2018).","journal-title":"Science"},{"key":"1140_CR33","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/s41591-020-0881-9","volume":"26","author":"R Murugan","year":"2020","unstructured":"Murugan, R. et al. Evolution of protective human antibodies against Plasmodium falciparum circumsporozoite protein repeat motifs. Nat. Med. 26, 1135\u20131145 (2020).","journal-title":"Nat. Med."},{"key":"1140_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21221-4","volume":"12","author":"T Pholcharee","year":"2021","unstructured":"Pholcharee, T. et al. Structural and biophysical correlation of anti-NANP antibodies with in vivo protection against P. falciparum. Nat. Commun. 12, 1063 (2021).","journal-title":"Nat. Commun."},{"key":"1140_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40151-x","volume":"14","author":"GM Martin","year":"2023","unstructured":"Martin, G. M. et al. Affinity-matured homotypic interactions induce spectrum of PfCSP structures that influence protection from malaria infection. Nat. Commun. 14, 4546 (2023).","journal-title":"Nat. Commun."},{"key":"1140_CR36","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.str.2023.02.009","volume":"31","author":"P Tripathi","year":"2023","unstructured":"Tripathi, P. et al. Cryo-EM structures of anti-malarial antibody L9 with circumsporozoite protein reveal trimeric L9 association and complete 27-residue epitope. Structure 31, 480\u2013491.e4 (2023).","journal-title":"Structure"},{"key":"1140_CR37","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aau8529","volume":"4","author":"D Oyen","year":"2018","unstructured":"Oyen, D. et al. Cryo-EM structure of P. falciparum circumsporozoite protein with a vaccine-elicited antibody is stabilized by somatically mutated inter-Fab contacts. Sci. Adv. 4, eaau8529 (2018).","journal-title":"Sci. Adv."},{"key":"1140_CR38","doi-asserted-by":"publisher","first-page":"26951","DOI":"10.1074\/jbc.M109.013706","volume":"284","author":"ML Plassmeyer","year":"2009","unstructured":"Plassmeyer, M. L. et al. Structure of the Plasmodium falciparum circumsporozoite protein, a leading malaria vaccine candidate. J. Biol. Chem. 284, 26951\u201326963 (2009).","journal-title":"J. Biol. Chem."},{"key":"1140_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-022-00430-y","volume":"7","author":"MD Langowski","year":"2022","unstructured":"Langowski, M. D. et al. Restricted valency (NPNA)n repeats and junctional epitope-based circumsporozoite protein vaccines against Plasmodium falciparum. npj Vaccines 7, 1\u201311 (2022).","journal-title":"npj Vaccines"},{"key":"1140_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00653-7","volume":"8","author":"J Ludwig","year":"2023","unstructured":"Ludwig, J. et al. Glycosylated nanoparticle-based PfCSP vaccine confers long-lasting antibody responses and sterile protection in mouse malaria model. NPJ Vaccines 8, 52 (2023).","journal-title":"NPJ Vaccines"},{"key":"1140_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-020-00274-4","volume":"6","author":"L Jel\u00ednkov\u00e1","year":"2021","unstructured":"Jel\u00ednkov\u00e1, L. et al. An epitope-based malaria vaccine targeting the junctional region of circumsporozoite protein. npj Vaccines 6, 1\u201310 (2021).","journal-title":"npj Vaccines"},{"key":"1140_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-00272-6","volume":"6","author":"JM Calvo-Calle","year":"2021","unstructured":"Calvo-Calle, J. M., Mitchell, R., Altszuler, R., Othoro, C. & Nardin, E. Identification of a neutralizing epitope within minor repeat region of Plasmodium falciparum CS protein. NPJ Vaccines 6, 10 (2021).","journal-title":"NPJ Vaccines"},{"key":"1140_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00302-x","volume":"6","author":"E Atcheson","year":"2021","unstructured":"Atcheson, E., Hill, A. V. S. & Reyes-Sandoval, A. A VLP for validation of the Plasmodium falciparum circumsporozoite protein junctional epitope for vaccine development. NPJ Vaccines 6, 46 (2021).","journal-title":"NPJ Vaccines"},{"key":"1140_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-022-00457-1","volume":"7","author":"L Jel\u00ednkov\u00e1","year":"2022","unstructured":"Jel\u00ednkov\u00e1, L. et al. A vaccine targeting the L9 epitope of the malaria circumsporozoite protein confers protection from blood-stage infection in a mouse challenge model. npj Vaccines 7, 1\u20134 (2022).","journal-title":"npj Vaccines"},{"key":"1140_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010999","volume":"18","author":"I Kucharska","year":"2022","unstructured":"Kucharska, I. et al. High-density binding to Plasmodium falciparum circumsporozoite protein repeats by inhibitory antibody elicited in mouse with human immunoglobulin repertoire. PLoS Pathog. 18, e1010999 (2022).","journal-title":"PLoS Pathog."},{"key":"1140_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38509-2","volume":"14","author":"GM Martin","year":"2023","unstructured":"Martin, G. M. et al. Structural basis of epitope selectivity and potent protection from malaria by PfCSP antibody L9. Nat. Commun. 14, 2815 (2023).","journal-title":"Nat. Commun."},{"key":"1140_CR47","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/nri2868","volume":"10","author":"MF Bachmann","year":"2010","unstructured":"Bachmann, M. F. & Jennings, G. T. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 10, 787\u2013796 (2010).","journal-title":"Nat. Rev. Immunol."},{"key":"1140_CR48","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.immuni.2020.08.001","volume":"53","author":"Y Kato","year":"2020","unstructured":"Kato, Y. et al. Multifaceted effects of antigen valency on b cell response composition and differentiation in vivo. Immunity 53, 548\u2013563.e8 (2020).","journal-title":"Immunity"},{"key":"1140_CR49","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.csbj.2015.11.001","volume":"14","author":"J L\u00f3pez-Sagaseta","year":"2016","unstructured":"L\u00f3pez-Sagaseta, J., Malito, E., Rappuoli, R. & Bottomley, M. J. Self-assembling protein nanoparticles in the design of vaccines. Comput. Struct. Biotechnol. J. 14, 58\u201368 (2016).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"1140_CR50","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1038\/nmat3775","volume":"12","author":"DJ Irvine","year":"2013","unstructured":"Irvine, D. J., Swartz, M. A. & Szeto, G. L. Engineering synthetic vaccines using cues from natural immunity. Nat. Mater. 12, 978\u2013990 (2013).","journal-title":"Nat. Mater."},{"key":"1140_CR51","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1093\/infdis\/171.6.1576","volume":"171","author":"DM Gordon","year":"1995","unstructured":"Gordon, D. M. et al. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J. Infect. Dis. 171, 1576\u20131585 (1995).","journal-title":"J. Infect. Dis."},{"key":"1140_CR52","doi-asserted-by":"publisher","first-page":"272","DOI":"10.3390\/vaccines9030272","volume":"9","author":"JR Francica","year":"2021","unstructured":"Francica, J. R. et al. Design of Alphavirus Virus-Like Particles Presenting Circumsporozoite Junctional Epitopes That Elicit Protection against Malaria. Vaccines (Basel) 9, 272 (2021).","journal-title":"Vaccines (Basel)"},{"key":"1140_CR53","doi-asserted-by":"crossref","unstructured":"Whitacre, D. C. et al. P. falciparum and P. vivax Epitope-Focused VLPs Elicit Sterile Immunity to Blood Stage Infections. PLoS One 10, e0124856 (2015).","DOI":"10.1371\/journal.pone.0124856"},{"key":"1140_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-12-136","volume":"12","author":"ME McCoy","year":"2013","unstructured":"McCoy, M. E. et al. Mechanisms of protective immune responses induced by the Plasmodium falciparum circumsporozoite protein-based, self-assembling protein nanoparticle vaccine. Malar. J. 12, 136 (2013).","journal-title":"Malar. J."},{"key":"1140_CR55","doi-asserted-by":"publisher","first-page":"3114","DOI":"10.1073\/pnas.1911792117","volume":"117","author":"MD Langowski","year":"2020","unstructured":"Langowski, M. D. et al. Optimization of a Plasmodium falciparum circumsporozoite protein repeat vaccine using the tobacco mosaic virus platform. Proc. Natl Acad. Sci. Usa. 117, 3114\u20133122 (2020).","journal-title":"Proc. Natl Acad. Sci. Usa."},{"key":"1140_CR56","doi-asserted-by":"crossref","unstructured":"Khan, F. et al. Head-to-head comparison of soluble vs. Q\u03b2 VLP circumsporozoite protein vaccines reveals selective enhancement of NANP repeat responses. PLoS One 10, e0142035 (2015).","DOI":"10.1371\/journal.pone.0142035"},{"key":"1140_CR57","doi-asserted-by":"publisher","first-page":"641421","DOI":"10.3389\/fimmu.2021.641421","volume":"12","author":"L Kurtovic","year":"2021","unstructured":"Kurtovic, L. et al. Novel virus-like particle vaccine encoding the circumsporozoite protein of plasmodium falciparum is immunogenic and induces functional antibody responses in mice. Front. Immunol. 12, 641421 (2021).","journal-title":"Front. Immunol."},{"key":"1140_CR58","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1126\/science.aaf8818","volume":"353","author":"JB Bale","year":"2016","unstructured":"Bale, J. B. et al. Accurate design of megadalton-scale two-component icosahedral protein complexes. Science 353, 389\u2013394 (2016).","journal-title":"Science"},{"key":"1140_CR59","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.57659","volume":"9","author":"G Ueda","year":"2020","unstructured":"Ueda, G. et al. Tailored design of protein nanoparticle scaffolds for multivalent presentation of viral glycoprotein antigens. Elife 9, e57659 (2020).","journal-title":"Elife"},{"key":"1140_CR60","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/j.cell.2019.01.046","volume":"176","author":"J Marcandalli","year":"2019","unstructured":"Marcandalli, J. et al. Induction of potent neutralizing antibody responses by a designed protein nanoparticle vaccine for respiratory syncytial virus. Cell 176, 1420\u20131431.e17 (2019).","journal-title":"Cell"},{"key":"1140_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12080-1","volume":"10","author":"PJM Brouwer","year":"2019","unstructured":"Brouwer, P. J. M. et al. Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle. Nat. Commun. 10, 4272 (2019).","journal-title":"Nat. Commun."},{"key":"1140_CR62","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.cell.2020.10.043","volume":"183","author":"AC Walls","year":"2020","unstructured":"Walls, A. C. et al. Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines forSARS-CoV-2. Cell 183, 1367\u20131382.e17 (2020).","journal-title":"Cell"},{"key":"1140_CR63","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/s41586-021-03365-x","volume":"592","author":"S Boyoglu-Barnum","year":"2021","unstructured":"Boyoglu-Barnum, S. et al. Quadrivalent influenza nanoparticle vaccines induce broad protection. Nature 592, 623\u2013628 (2021).","journal-title":"Nature"},{"key":"1140_CR64","doi-asserted-by":"publisher","first-page":"102140","DOI":"10.1016\/j.eclinm.2023.102140","volume":"64","author":"JY Song","year":"2023","unstructured":"Song, J. Y. et al. Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: interim results of a randomised, active-controlled, observer-blinded, phase 3 trial. EClinicalMedicine 64, 102140 (2023).","journal-title":"EClinicalMedicine"},{"key":"1140_CR65","unstructured":"Pancera, M. & Weidle, C. Circumsporozoite Proteins With Increased Expression In Mammalian Cells. https:\/\/patents.google.com\/patent\/US11896655B2\/en (2024)."},{"key":"1140_CR66","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.cell.2007.09.013","volume":"131","author":"AP Singh","year":"2007","unstructured":"Singh, A. P. et al. Plasmodium circumsporozoite protein promotes the development of the liver stages of the parasite. Cell 131, 492\u2013504 (2007).","journal-title":"Cell"},{"key":"1140_CR67","doi-asserted-by":"publisher","first-page":"4746","DOI":"10.1128\/jvi.74.10.4746-4754.2000","volume":"74","author":"X Yang","year":"2000","unstructured":"Yang, X. et al. Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution. J. Virol. 74, 4746\u20134754 (2000).","journal-title":"J. Virol."},{"key":"1140_CR68","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/nature16988","volume":"531","author":"AC Walls","year":"2016","unstructured":"Walls, A. C. et al. Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer. Nature 531, 114\u2013117 (2016).","journal-title":"Nature"},{"key":"1140_CR69","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/nature17200","volume":"531","author":"RN Kirchdoerfer","year":"2016","unstructured":"Kirchdoerfer, R. N. et al. Pre-fusion structure of a human coronavirus spike protein. Nature 531, 118\u2013121 (2016).","journal-title":"Nature"},{"key":"1140_CR70","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1074\/jbc.RA119.011268","volume":"295","author":"SK Singh","year":"2020","unstructured":"Singh, S. K. et al. The Plasmodium falciparum circumsporozoite protein produced in Lactococcus lactis is pure and stable. J. Biol. Chem. 295, 403\u2013414 (2020).","journal-title":"J. Biol. Chem."},{"key":"1140_CR71","doi-asserted-by":"publisher","first-page":"E690","DOI":"10.1073\/pnas.1115485109","volume":"109","author":"B Zakeri","year":"2012","unstructured":"Zakeri, B. et al. Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin. Proc. Natl Acad. Sci. Usa. 109, E690\u2013E697 (2012).","journal-title":"Proc. Natl Acad. Sci. Usa."},{"key":"1140_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34961-8","volume":"13","author":"K Sliepen","year":"2022","unstructured":"Sliepen, K. et al. Induction of cross-neutralizing antibodies by a permuted hepatitis C virus glycoprotein nanoparticle vaccine candidate. Nat. Commun. 13, 7271 (2022).","journal-title":"Nat. Commun."},{"key":"1140_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30222-w","volume":"13","author":"Y-F Kang","year":"2022","unstructured":"Kang, Y.-F. et al. Quadrivalent mosaic HexaPro-bearing nanoparticle vaccine protects against infection of SARS-CoV-2 variants. Nat. Commun. 13, 2674 (2022).","journal-title":"Nat. Commun."},{"key":"1140_CR74","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1080\/14760584.2020.1745636","volume":"19","author":"CR Alving","year":"2020","unstructured":"Alving, C. R., Peachman, K. K., Matyas, G. R., Rao, M. & Beck, Z. Army Liposome formulation (ALF) family of vaccine adjuvants. Expert Rev. Vaccines 19, 279\u2013292 (2020).","journal-title":"Expert Rev. Vaccines"},{"key":"1140_CR75","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1586\/erv.11.25","volume":"10","author":"K L\u00f6vgren Bengtsson","year":"2011","unstructured":"L\u00f6vgren Bengtsson, K., Morein, B. & Osterhaus, A. D. ISCOM technology-based matrix MTM adjuvant: success in future vaccines relies on formulation. Expert Rev. Vaccines 10, 401\u2013403 (2011).","journal-title":"Expert Rev. Vaccines"},{"key":"1140_CR76","doi-asserted-by":"publisher","first-page":"101245","DOI":"10.1016\/j.xcrm.2023.101245","volume":"4","author":"S Reinke","year":"2023","unstructured":"Reinke, S. et al. Emulsion and liposome-based adjuvanted R21 vaccine formulations mediate protection against malaria through distinct immune mechanisms. Cell Rep. Med. 4, 101245 (2023).","journal-title":"Cell Rep. Med."},{"key":"1140_CR77","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-020-03181-0","volume":"19","author":"R Raghunandan","year":"2020","unstructured":"Raghunandan, R. et al. Characterization of two in vivo challenge models to measure functional activity of monoclonal antibodies to Plasmodium falciparum circumsporozoite protein. Malar. J. 19, 113 (2020).","journal-title":"Malar. J."},{"key":"1140_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100780","volume":"3","author":"JC Kraft","year":"2022","unstructured":"Kraft, J. C. et al. Antigen- and scaffold-specific antibody responses to protein nanoparticle immunogens. Cell Rep. Med 3, 100780 (2022).","journal-title":"Cell Rep. Med"},{"key":"1140_CR79","doi-asserted-by":"publisher","first-page":"4000","DOI":"10.4049\/jimmunol.142.11.4000","volume":"142","author":"AS de Groot","year":"1989","unstructured":"de Groot, A. S. et al. Human T cell recognition of polymorphic epitopes from malaria circumsporozoite protein. J. Immunol. 142, 4000\u20134005 (1989).","journal-title":"J. Immunol."},{"key":"1140_CR80","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1126\/science.2434994","volume":"235","author":"MF Good","year":"1987","unstructured":"Good, M. F. et al. Construction of synthetic immunogen: use of new T-helper epitope on malaria circumsporozoite protein. Science 235, 1059\u20131062 (1987).","journal-title":"Science"},{"key":"1140_CR81","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1084\/jem.20170869","volume":"215","author":"SW Scally","year":"2018","unstructured":"Scally, S. W. et al. Rare PfCSP C-terminal antibodies induced by live sporozoite vaccination are ineffective against malaria infection. J. Exp. Med. 215, 63\u201375 (2018).","journal-title":"J. Exp. Med."},{"key":"1140_CR82","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010409","volume":"18","author":"N Beutler","year":"2022","unstructured":"Beutler, N. et al. A novel CSP C-terminal epitope targeted by an antibody with protective activity against Plasmodium falciparum. PLoS Pathog. 18, e1010409 (2022).","journal-title":"PLoS Pathog."},{"key":"1140_CR83","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00372-x","volume":"6","author":"KE Seaton","year":"2021","unstructured":"Seaton, K. E. et al. Subclass and avidity of circumsporozoite protein specific antibodies associate with protection status against malaria infection. NPJ Vaccines 6, 110 (2021).","journal-title":"NPJ Vaccines"},{"key":"1140_CR84","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10195-z","volume":"10","author":"C Doba\u00f1o","year":"2019","unstructured":"Doba\u00f1o, C. et al. Concentration and avidity of antibodies to different circumsporozoite epitopes correlate with RTS,S\/AS01E malaria vaccine efficacy. Nat. Commun. 10, 2174 (2019).","journal-title":"Nat. Commun."},{"key":"1140_CR85","doi-asserted-by":"crossref","unstructured":"Thai, E. et al. Molecular determinants of cross-reactivity and potency by VH3-33 antibodies against the Plasmodium falciparum circumsporozoite protein. Cell Rep. 42, 113330 (2023).","DOI":"10.1016\/j.celrep.2023.113330"},{"key":"1140_CR86","doi-asserted-by":"publisher","first-page":"113553","DOI":"10.1016\/j.celrep.2023.113553","volume":"42","author":"A Dosey","year":"2023","unstructured":"Dosey, A. et al. Combinatorial immune refocusing within the influenza hemagglutinin RBD improves cross-neutralizing antibody responses. Cell Rep. 42, 113553 (2023).","journal-title":"Cell Rep."},{"key":"1140_CR87","doi-asserted-by":"publisher","first-page":"5432","DOI":"10.1016\/j.cell.2021.09.015","volume":"184","author":"AC Walls","year":"2021","unstructured":"Walls, A. C. et al. Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. Cell 184, 5432\u20135447.e16 (2021).","journal-title":"Cell"},{"key":"1140_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.105649","volume":"25","author":"M Brinkkemper","year":"2022","unstructured":"Brinkkemper, M. et al. Co-display of diverse spike proteins on nanoparticles broadens sarbecovirus neutralizing antibody responses. iScience 25, 105649 (2022).","journal-title":"iScience"},{"key":"1140_CR89","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41661-4","volume":"14","author":"GB Hutchinson","year":"2023","unstructured":"Hutchinson, G. B. et al. Nanoparticle display of prefusion coronavirus spike elicits S1-focused cross-reactive antibody response against diverse coronavirus subgenera. Nat. Commun. 14, 6195 (2023).","journal-title":"Nat. Commun."},{"key":"1140_CR90","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41590-018-0305-x","volume":"20","author":"M Kanekiyo","year":"2019","unstructured":"Kanekiyo, M. et al. Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses. Nat. Immunol. 20, 362\u2013372 (2019).","journal-title":"Nat. Immunol."},{"key":"1140_CR91","doi-asserted-by":"publisher","unstructured":"Wang, E. et al. Designed mosaic nanoparticles enhance cross-reactive immune responses in mice. bioRxiv https:\/\/doi.org\/10.1101\/2024.02.28.582544 (2024).","DOI":"10.1101\/2024.02.28.582544"},{"key":"1140_CR92","doi-asserted-by":"publisher","unstructured":"Cohen, A. A. et al. Mosaic sarbecovirus vaccination elicits cross-reactive responses in pre-immunized animals. bioRxiv https:\/\/doi.org\/10.1101\/2024.02.08.576722 (2024).","DOI":"10.1101\/2024.02.08.576722"},{"key":"1140_CR93","doi-asserted-by":"publisher","unstructured":"Hills, R. A. et al. Multiviral quartet nanocages elicit broad anti-coronavirus responses for proactive vaccinology. bioRxiv https:\/\/doi.org\/10.1101\/2023.02.24.529520 (2023).","DOI":"10.1101\/2023.02.24.529520"},{"key":"1140_CR94","doi-asserted-by":"publisher","DOI":"10.1126\/science.abq0839","volume":"377","author":"AA Cohen","year":"2022","unstructured":"Cohen, A. A. et al. Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models. Science 377, eabq0839 (2022).","journal-title":"Science"},{"key":"1140_CR95","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1126\/science.abf6840","volume":"371","author":"AA Cohen","year":"2021","unstructured":"Cohen, A. A. et al. Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice. Science 371, 735\u2013741 (2021).","journal-title":"Science"},{"key":"1140_CR96","doi-asserted-by":"publisher","first-page":"e0247963","DOI":"10.1371\/journal.pone.0247963","volume":"16","author":"AA Cohen","year":"2021","unstructured":"Cohen, A. A. et al. Construction, characterization, and immunization of nanoparticles that display a diverse array of influenza HA trimers. PLoS One 16, e0247963 (2021).","journal-title":"PLoS One"},{"key":"1140_CR97","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21251-y","volume":"12","author":"AJ Wargacki","year":"2021","unstructured":"Wargacki, A. J. et al. Complete and cooperative in vitro assembly of computationally designed self-assembling protein nanomaterials. Nat. Commun. 12, 883 (2021).","journal-title":"Nat. Commun."},{"key":"1140_CR98","doi-asserted-by":"publisher","first-page":"110217","DOI":"10.1016\/j.celrep.2021.110217","volume":"38","author":"BJ Read","year":"2022","unstructured":"Read, B. J. et al. Mannose-binding lectin and complement mediate follicular localization and enhanced immunogenicity of diverse protein nanoparticle immunogens. Cell Rep. 38, 110217 (2022).","journal-title":"Cell Rep."},{"key":"1140_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100658","volume":"3","author":"H Malhi","year":"2022","unstructured":"Malhi, H. et al. Immunization with a self-assembling nanoparticle vaccine displaying EBV gH\/gL protects humanized mice against lethal viral challenge. Cell Rep. Med 3, 100658 (2022).","journal-title":"Cell Rep. Med"},{"key":"1140_CR100","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1016\/j.immuni.2023.08.011","volume":"56","author":"S Ols","year":"2023","unstructured":"Ols, S. et al. Multivalent antigen display on nanoparticle immunogens increases B cell clonotype diversity and neutralization breadth to pneumoviruses. Immunity 56, 2425\u20132441.e14 (2023).","journal-title":"Immunity"},{"key":"1140_CR101","doi-asserted-by":"crossref","unstructured":"Wu, Y., Ding, Y. & Shen, C. A systematic review of t cell epitopes defined from the proteome of hepatitis B virus. Vaccines (Basel) 10, 257 (2022).","DOI":"10.3390\/vaccines10020257"},{"key":"1140_CR102","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abo4184","volume":"8","author":"H Liu","year":"2022","unstructured":"Liu, H. et al. Cryo-EM structures of human hepatitis B and woodchuck hepatitis virus small spherical subviral particles. Sci. Adv. 8, eabo4184 (2022).","journal-title":"Sci. Adv."},{"key":"1140_CR103","doi-asserted-by":"publisher","first-page":"10414","DOI":"10.1016\/S0021-9258(18)34034-1","volume":"257","author":"DL Peterson","year":"1982","unstructured":"Peterson, D. L., Nath, N. & Gavilanes, F. Structure of hepatitis B surface antigen. Correlation of subtype with amino acid sequence and location of the carbohydrate moiety. J. Biol. Chem. 257, 10414\u201310420 (1982).","journal-title":"J. Biol. Chem."},{"key":"1140_CR104","doi-asserted-by":"publisher","DOI":"10.1002\/pro.4852","volume":"33","author":"R Geens","year":"2024","unstructured":"Geens, R. et al. Biophysical characterization of the Plasmodium falciparum circumsporozoite protein\u2019s N-terminal domain. Protein Sci. 33, e4852 (2024).","journal-title":"Protein Sci."},{"key":"1140_CR105","doi-asserted-by":"publisher","unstructured":"Nepal, Y. et al. Virus-like particle vaccines targeting a key epitope in circumsporozoite protein provide sterilizing immunity against malaria in a mouse challenge model. bioRxiv 2025.03.03.641239; https:\/\/doi.org\/10.1101\/2025.03.03.641239.","DOI":"10.1101\/2025.03.03.641239"},{"key":"1140_CR106","doi-asserted-by":"publisher","first-page":"112681","DOI":"10.1016\/j.celrep.2023.112681","volume":"42","author":"MC Aguirre-Botero","year":"2023","unstructured":"Aguirre-Botero, M. C. et al. Cytotoxicity of human antibodies targeting the circumsporozoite protein is amplified by 3D substrate and correlates with protection. Cell Rep. 42, 112681 (2023).","journal-title":"Cell Rep."},{"key":"1140_CR107","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-018-1186-4","volume":"16","author":"I Ubillos","year":"2018","unstructured":"Ubillos, I. et al. Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S\/AS01E vaccination in African children. BMC Med 16, 197 (2018).","journal-title":"BMC Med"},{"key":"1140_CR108","doi-asserted-by":"crossref","unstructured":"Suscovich, T. J. et al. Mapping functional humoral correlates of protection against malaria challenge following RTS,S\/AS01 vaccination. Sci. Transl. Med. 12, eabb4757 (2020).","DOI":"10.1126\/scitranslmed.abb4757"},{"key":"1140_CR109","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010133","volume":"17","author":"LT Wang","year":"2021","unstructured":"Wang, L. T. et al. Protective effects of combining monoclonal antibodies and vaccines against the Plasmodium falciparum circumsporozoite protein. PLoS Pathog. 17, e1010133 (2021).","journal-title":"PLoS Pathog."},{"key":"1140_CR110","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1056\/NEJMoa1505819","volume":"373","author":"DE Neafsey","year":"2015","unstructured":"Neafsey, D. E. et al. Genetic diversity and protective efficacy of the RTS,S\/AS01 malaria vaccine. N. Engl. J. Med. 373, 2025\u20132037 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1140_CR111","doi-asserted-by":"crossref","unstructured":"Hayashi, C. T. H. et al. Antibodies elicited by Plasmodium falciparum circumsporozoite proteins lacking sequentially deleted C-terminal amino acids reveal mouse strain and epitopes specific differences. Vaccine 41, 6824\u20136833 (2023).","DOI":"10.1016\/j.vaccine.2023.10.009"},{"key":"1140_CR112","doi-asserted-by":"crossref","unstructured":"Ellis, D. et al. Antigen spacing on protein nanoparticles influences antibody responses to vaccination. Cell Rep. 42, 113552 (2023).","DOI":"10.1016\/j.celrep.2023.113552"},{"key":"1140_CR113","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/BF02788751","volume":"18","author":"J Alexander","year":"1998","unstructured":"Alexander, J. et al. The optimization of helper T lymphocyte (HTL) function in vaccine development. Immunol. Res. 18, 79\u201392 (1998).","journal-title":"Immunol. Res."},{"key":"1140_CR114","doi-asserted-by":"crossref","unstructured":"Zavala, F. RTS,S: the first malaria vaccine. J. Clin. Invest. 132, e156588 (2022).","DOI":"10.1172\/JCI156588"},{"key":"1140_CR115","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-019-3055-9","volume":"18","author":"Y Flores-Garcia","year":"2019","unstructured":"Flores-Garcia, Y. et al. Optimization of an in vivo model to study immunity to Plasmodium falciparum pre-erythrocytic stages. Malar. J. 18, 426 (2019).","journal-title":"Malar. J."},{"key":"1140_CR116","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jconrel.2018.02.006","volume":"275","author":"Z Beck","year":"2018","unstructured":"Beck, Z., Torres, O. B., Matyas, G. R., Lanar, D. E. & Alving, C. R. Immune response to antigen adsorbed to aluminum hydroxide particles: effects of co-adsorption of ALF or ALFQ adjuvant to the aluminum-antigen complex. J. Control. Release 275, 12\u201319 (2018).","journal-title":"J. Control. Release"},{"key":"1140_CR117","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","volume":"596","author":"J Jumper","year":"2021","unstructured":"Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583\u2013589 (2021).","journal-title":"Nature"},{"key":"1140_CR118","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/pro.3943","volume":"30","author":"EF Pettersen","year":"2021","unstructured":"Pettersen, E. F. et al. UCSF ChimeraX: Structure visualization for researchers, educators, and developers. Protein Sci. 30, 70\u201382 (2021).","journal-title":"Protein Sci."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01140-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01140-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01140-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T08:04:40Z","timestamp":1746432280000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01140-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,5]]},"references-count":118,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1140"],"URL":"https:\/\/doi.org\/10.1038\/s41541-025-01140-x","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,5]]},"assertion":[{"value":"7 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"87"}}